New drug APR-1051 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called APR-1051 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a solid tumor that is advanced or has spread and hasn't responded to standard treatments
- Your tumor must be measurable or evaluable by scans
- You should be generally active (able to do light housework or office work)
- You must have recovered from side effects of prior cancer treatments (except for mild hair loss or nerve issues)
- You cannot have had chemotherapy or radiation in the last 3 weeks, or major surgery in the last 3 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
This study is testing a new drug called SHR-1049 for people with advanced solid tumors (cancers that have spread). It looks at safety, how the drug moves through the body, and whether it helps shrink tumors. You may be eligible if you have tried standard treatment without success or no standard treatment exists.
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.